ACUR Acura Pharmaceuticals Inc

Price (delayed)

$0.5326

Market cap

$11.77M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.03

Enterprise value

$17.95M

Highlights
ACUR's EPS has soared by 80% YoY and by 25% from the previous quarter
ACUR's net income has surged by 76% year-on-year and by 28% since the previous quarter
ACUR's equity is down by 16% YoY and by 4.2% QoQ
Acura Pharmaceuticals's revenue has decreased by 15% YoY and by 13% QoQ

Key stats

What are the main financial stats of ACUR
Market
Shares outstanding
22.1M
Market cap
$11.77M
Enterprise value
$17.95M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
5.54
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.75
Earnings
Revenue
$3.12M
EBIT
-$421,000
EBITDA
-$344,000
Free cash flow
-$1.38M
Per share
EPS
-$0.03
Free cash flow per share
-$0.04
Book value per share
-$0.28
Revenue per share
$0.1
TBVPS
$0.06
Balance sheet
Total assets
$1.92M
Total liabilities
$8.06M
Debt
$6.54M
Equity
-$6.14M
Working capital
-$6.31M
Liquidity
Debt to equity
-1.06
Current ratio
0.18
Quick ratio
0.17
Net debt/EBITDA
-17.95
Margins
EBITDA margin
-11%
Gross margin
100%
Net margin
-27.9%
Operating margin
-13.5%
Efficiency
Return on assets
-41.6%
Return on equity
N/A
Return on invested capital
-22.9%
Return on capital employed
N/A
Return on sales
-13.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ACUR stock price

How has the Acura Pharmaceuticals stock price performed over time
Intraday
0.49%
1 week
-7.37%
1 month
-14.44%
1 year
142.09%
YTD
153.62%
QTD
-19.3%

Financial performance

How have Acura Pharmaceuticals's revenue and profit performed over time
Revenue
$3.12M
Gross profit
$3.12M
Operating income
-$421,000
Net income
-$872,000
Gross margin
100%
Net margin
-27.9%
ACUR's net income has surged by 76% year-on-year and by 28% since the previous quarter
Acura Pharmaceuticals's net margin has surged by 71% YoY and by 17% QoQ
ACUR's operating income is up by 44% since the previous quarter and by 20% year-on-year
ACUR's operating margin is up by 36% from the previous quarter and by 6% YoY

Growth

What is Acura Pharmaceuticals's growth rate over time

Valuation

What is Acura Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
5.54
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.75
ACUR's EPS has soared by 80% YoY and by 25% from the previous quarter
ACUR's equity is down by 16% YoY and by 4.2% QoQ
The stock's price to sales (P/S) is 131% more than its last 4 quarters average of 2.4 but 11% less than its 5-year quarterly average of 6.2
Acura Pharmaceuticals's revenue has decreased by 15% YoY and by 13% QoQ

Efficiency

How efficient is Acura Pharmaceuticals business performance
ACUR's ROS has soared by 84% YoY and by 36% from the previous quarter
Acura Pharmaceuticals's ROA has soared by 72% YoY and by 27% from the previous quarter
The company's return on invested capital has surged by 69% YoY and by 52% QoQ

Dividends

What is ACUR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ACUR.

Financial health

How did Acura Pharmaceuticals financials performed over time
The total assets is 76% smaller than the total liabilities
ACUR's quick ratio is up by 21% since the previous quarter
Acura Pharmaceuticals's current ratio has increased by 13% from the previous quarter but it has decreased by 5% YoY
ACUR's equity is down by 16% YoY and by 4.2% QoQ
Acura Pharmaceuticals's debt has increased by 9% YoY and by 4.2% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.